Udonitrectag

DB18013InvestigationalSmall molecule

Udonitrectag: Overview.

Mechanism: Pharmacologically active on High affinity nerve growth factor receptor, BDNF/NT-3 growth factors receptor, and Tumor necrosis factor receptor superfamily member 16
Curator reviewed
Formula / weight: C₂₀H₁₉NO₅ · 353.374 g/mol (avg)
Also known as: (1s,4r,5r,7s)-2-oxo-3,4-bis(phenylmethyl)-6,8-dioxa-3-azabicyclo(3.2.1)octane-7-carboxylate · (1s,4r,5r,7s)-3, 4-dibenzyl-2-oxo-6, 8-dioxa-3-azabicyclo (3.2.1) octane-7-carboxylic acid · 3, 4-dibenzyl-2-oxo-6, 8-dioxa-3-azabicyclo (3.2.1) octane-7-carboxylic acid, (1s,4r,5r,7s)- · 6,8-dioxa-3-azabicyclo(3.2.1)octane-7-carboxylic acid, 2-oxo-3,4-bis(phenylmethyl)-, (1s,4r,5r,7s)- · Rec-0559 (nerve growth factor mimetic)
Code names: REC-0559

Resolves to

Compound

Structure

InChIKeySEKGLVUAECPQQM-NHAYFPRASA-NSMILESOC(=O)[C@H]1O[C@H]2O[C@@H]1C(=O)N(CC1=CC=CC=C1)[C@@H]2CC1=CC=CC=C1

Targets

What you can answer from here — as of September 12, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Udonitrectag, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.